Title
PnPP-19, a Synthetic and Nontoxic Peptide Designed from a Phoneutria nigriventer Toxin, Potentiates Erectile Function via NO/cGMP
Date Issued
01 November 2015
Access level
metadata only access
Resource Type
journal article
Author(s)
Silva C.N.
Nunes K.P.
Torres F.S.
Cassoli J.S.
Santos D.M.
Almeida F.D.M.
Matavel A.
Cruz J.S.
Santos-Miranda A.
Nunes A.D.C.
Castro C.H.
Machado De Ávila R.A.
Láuar S.S.
Felicori L.
Resende J.M.
Camargos E.R.D.S.
Borges M.H.
Cordeiro M.N.
Peigneur S.
Tytgat J.
De Lima M.E.
Universidade Federal de Minas Gerais
Publisher(s)
Elsevier Inc.
Abstract
Purpose We designed a peptide, PnPP-19, comprising the potential active core of the Phoneutria nigriventer native toxin PnTx2-6. We investigated its role on erectile function, and its toxicity and immunogenicity. Materials and Methods Erectile function was evaluated by the intracavernous pressure-to-mean arterial pressure ratio during electrical field stimulation on rat pelvic ganglia. Cavernous strips were contracted with phenylephrine and relaxation was induced by electrical field stimulation with or without PnPP-19 (10-8 M). Activity on sodium channels was evaluated by electrophysiological screening of transfected channels on Xenopus oocytes and dorsal root ganglion cells. Antibodies were detected by indirect enzyme-linked immunosorbent assay in mice previously treated with the peptide. Histopathological studies were performed with mouse organs treated with different doses of PnPP-19. Results PnPP-19 was able to potentiate erection at 4 and 8 Hz in vivo and ex vivo. It showed no toxicity and low immunogenicity in mice, and did not affect sodium channels or rat hearts. PnPP-19 increased cyclic guanosine monophosphate levels at 8 Hz. This effect was inhibited by L-NAME (10-4 M). Erectile function was partially inhibited by 7-nitroindazole (10-5 M), a selective inhibitor of neuronal nitric oxide synthase. Conclusions PnPP-19 potentiates erection in vivo and ex vivo via the nitric oxide/cyclic guanosine monophosphate pathway. It does not affect sodium channels or rat hearts and shows no toxicity and low immunogenicity. These findings make it a promising candidate as a novel drug in the therapy of erectile dysfunction.
Start page
1481
End page
1490
Volume
194
Issue
5
Language
English
OCDE Knowledge area
Urología, Nefrología
Subjects
Scopus EID
2-s2.0-84943632779
PubMed ID
Source
Journal of Urology
ISSN of the container
00225347
Sponsor(s)
Supported by INCTTOX, CAPES, FAPEMIG and CNPq, American Heart Association Grant SDG 12SDG12080023 (KPN), and Fonds Wetenschappelijk Onderzoek Vlaanderen Grants G.0433.12 and G.A071.10N, Inter-University Attraction Poles Program Grant IUAP 7/10 from Belgian State, Belgian Science Policy and KU Leuven Grant OT/12/081 (JT).
Sources of information:
Directorio de Producción Científica
Scopus